/
Oncology
Anal Cancer
9
Pipeline Programs↗
8
Active Trials↗
8
Companies Involved↗
Anal Cancer is an early-stage landscape with 9 programs across 8 companies. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 28
Phase 31
Approved
No programs
Analysis
Modality Breakdown
9programs
Small molecule556%
Monoclonal antibody444%
Modality classified for 100% of 9 pipeline programs.
Analysis
Trial Status
15
clinical trials
Completed5 · 33%
Recruiting4 · 27%
Active, not recruiting2 · 13%
Withdrawn1 · 7%
Unknown status1 · 7%
Enrolling by invitation1 · 7%
Other1 · 7%
Clinical Trials
Trial Activity
15 trials
Adaptive Radiation in Anal Cancer
Recruiting·—·N/A·NCT05838391·20 enrolled
ctHPVDNA Adapted ChemoRadiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer (CHART-AC)
Recruiting·—·Phase 2·NCT07425054·33 enrolled
A Phase II Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
Recruiting·—·Phase 2·NCT06493019·23 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)